Brexpiprazole (Trade name: Rexulti) is an antipsychotic in the atypical antipsychotic class commonly used in the treatment of schizophrenia. It is also used as an adjunctive medication in major depressive disorder.
Brexpiprazole has features that both overlap and contrast with an older medication, aripiprazole. Brexpiprazole was developed due to concerns about impulse-control problems that developed in the use of aripiprazole (due to dopamine partial agonism). Brexpiprazole was thus designed with dopamine agonism “dialed back” a bit, and it generally has less problems with impulse-control symptoms.
| Substrate of (Metabolized by) | |
|---|---|
| Induces | |
| Inhibits |
| Starting | |
|---|---|
| Titration | |
| Maximum | |
| Taper |